Nurse Practitioner Loses Ground in DEA Controlled Substance Battle
Published Date: 10/30/2025
Notice
Summary
Dawn Evert, a nurse practitioner from Colorado, had her DEA registration suspended and then revoked because she prescribed dangerous drugs without proper medical reasons or monitoring. This decision protects public safety by stopping her from legally prescribing controlled substances. The revocation is final, even though her registration expired in August 2025, so she can’t prescribe these drugs anymore.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Nurse Practitioner
The DEA revoked Dawn Evert's Certificate of Registration No. ME1730870, effective December 1, 2025. Her registration had expired on August 31, 2025, but the Agency nevertheless revoked it and denied any pending applications to renew, modify, or obtain registration in Colorado, so she may no longer legally prescribe controlled substances.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-19705 — Lawrence Michael Willis, D.D.S.; Decision and Order
Dr. Lawrence Michael Willis from Colorado lost his DEA registration because he didn’t follow state rules about checking the Prescription Drug Monitoring Program. He didn’t ask for a hearing in time, so the government revoked his registration by default. This means he can’t legally handle controlled substances anymore, effective immediately, which could impact his dental practice and income.
Next: 2025-19708 — Pharmacy Place, Llc; Decision and Order
Pharmacy Place, LLC in Houston had its DEA registration suspended and is facing revocation because it filled many controlled substance prescriptions improperly and broke recordkeeping rules. This decision protects public health by stopping unsafe pharmacy practices. Pharmacy Place must fix these issues or lose its ability to handle controlled drugs, affecting their business and customers starting now.